Logo

Castle Biosciences DecisionDx-UMSeq Panel

Jan 12, 2018

Castle Biosciences has launched the DecisionDx-UMSeq panel, which uses next-generation sequencing to identify somatic mutations in genes relevant to uveal melanoma. The panel will evaluate DNA mutations in seven genes known to be relevant to UM: GNAQ, GNA11, PLCB4, CYSLTR2, SF3B1, exons 1-2 of EIF1AX, and coding exons of BAP1. While no currently available therapies target pathways affected by the gene mutations evaluated in the panel, the genomic information may be useful in the future to inform patient care as UM research and therapeutic options evolve, the company noted. The assay will complement Castle's DecisionDx-UM gene expression profile test for assessing likelihood of metastasis in UM.

Breaking News
The Scan

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.

Adenine Base Editor Targets SCID Mutation in New Study

Researchers from the University of California, Los Angeles, report in Cell that adenine base editing was able to produce functional T lymphocytes in a model of severe combined immune deficiency.

Researchers Find Gene Affecting Alkaline Sensitivity in Plants

Researchers from the Chinese Academy of Science have found a locus affecting alkaline-salinity sensitivity, which could aid in efforts to improve crop productivity, as they report in Science.

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.